HealthCor Management L.P. raised its stake in shares of Clovis Oncology Inc (NASDAQ:CLVS) by 50.4% during the 4th quarter, HoldingsChannel.com reports. The fund owned 973,840 shares of the biopharmaceutical company’s stock after purchasing an additional 326,420 shares during the quarter. Clovis Oncology makes up approximately 2.2% of HealthCor Management L.P.’s portfolio, making the stock its 23rd largest holding. HealthCor Management L.P.’s holdings in Clovis Oncology were worth $66,221,000 at the end of the most recent quarter.
A number of other institutional investors and hedge funds also recently bought and sold shares of the business. Amalgamated Bank lifted its stake in Clovis Oncology by 16.1% during the 3rd quarter. Amalgamated Bank now owns 5,587 shares of the biopharmaceutical company’s stock valued at $460,000 after acquiring an additional 776 shares during the period. Greenwood Capital Associates LLC lifted its stake in shares of Clovis Oncology by 21.6% in the 4th quarter. Greenwood Capital Associates LLC now owns 5,605 shares of the biopharmaceutical company’s stock worth $381,000 after purchasing an additional 996 shares during the period. Geode Capital Management LLC lifted its stake in shares of Clovis Oncology by 0.3% in the 4th quarter. Geode Capital Management LLC now owns 436,518 shares of the biopharmaceutical company’s stock worth $29,683,000 after purchasing an additional 1,206 shares during the period. Capital Analysts LLC bought a new position in shares of Clovis Oncology in the 3rd quarter worth approximately $111,000. Finally, Sheaff Brock Investment Advisors LLC lifted its stake in shares of Clovis Oncology by 30.1% in the 4th quarter. Sheaff Brock Investment Advisors LLC now owns 6,376 shares of the biopharmaceutical company’s stock worth $434,000 after purchasing an additional 1,476 shares during the period.
Shares of Clovis Oncology Inc (NASDAQ:CLVS) opened at $62.12 on Monday. The company has a debt-to-equity ratio of 0.77, a current ratio of 7.69 and a quick ratio of 7.35. Clovis Oncology Inc has a fifty-two week low of $45.42 and a fifty-two week high of $99.45.
In other Clovis Oncology news, insider Gillian C. Ivers-Read sold 3,000 shares of the stock in a transaction that occurred on Friday, December 15th. The shares were sold at an average price of $64.16, for a total transaction of $192,480.00. Following the completion of the sale, the insider now directly owns 182,583 shares of the company’s stock, valued at approximately $11,714,525.28. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, Director Thorlef Spickschen sold 4,500 shares of the stock in a transaction that occurred on Thursday, March 8th. The shares were sold at an average price of $61.47, for a total transaction of $276,615.00. Following the sale, the director now directly owns 12,118 shares of the company’s stock, valued at $744,893.46. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 22,500 shares of company stock valued at $1,371,210. Insiders own 12.50% of the company’s stock.
CLVS has been the topic of several recent research reports. Leerink Swann reiterated an “outperform” rating and issued a $90.00 price objective (down previously from $107.00) on shares of Clovis Oncology in a research note on Wednesday, November 15th. ValuEngine cut shares of Clovis Oncology from a “hold” rating to a “sell” rating in a research note on Tuesday, December 5th. BidaskClub raised shares of Clovis Oncology from a “strong sell” rating to a “sell” rating in a report on Saturday, December 9th. Oppenheimer reissued a “hold” rating on shares of Clovis Oncology in a report on Wednesday, December 20th. Finally, JPMorgan Chase & Co. reissued a “buy” rating on shares of Clovis Oncology in a report on Thursday, January 11th. One equities research analyst has rated the stock with a sell rating, six have assigned a hold rating and fourteen have assigned a buy rating to the company. The company has a consensus rating of “Buy” and an average price target of $87.84.
TRADEMARK VIOLATION NOTICE: This piece of content was published by Ticker Report and is owned by of Ticker Report. If you are viewing this piece of content on another site, it was stolen and republished in violation of U.S. and international copyright legislation. The legal version of this piece of content can be viewed at https://www.tickerreport.com/banking-finance/3257852/clovis-oncology-inc-clvs-shares-bought-by-healthcor-management-l-p.html.
About Clovis Oncology
Clovis Oncology, Inc is a biopharmaceutical company focused on acquiring, developing and commercializing anti-cancer agents in the United States, Europe and other international markets. The Company’s product candidates include Rociletinib, Rubraca (Rucaparib) and Lucitanib. Rucaparib is an oral, small molecule poly adenosine diphosphate (ADP)-ribose polymerase (PARP) inhibitor of PARP1, PARP2 and PARP3 approved as a monotherapy for the treatment of patients with deleterious breast cancer (BRCA) (human genes associated with the repair of damaged deoxyribonucleic acid (DNA)) mutation (germline and/or somatic) associated advanced ovarian cancer.
Want to see what other hedge funds are holding CLVS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Clovis Oncology Inc (NASDAQ:CLVS).
Receive News & Ratings for Clovis Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clovis Oncology and related companies with MarketBeat.com's FREE daily email newsletter.